Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Selank and Semax: what the research shows
Selank and Semax are paired on forums for anxiety and focus. Here is what published research shows about each, and why the combination has no clinical data.
Semaglutide gut transit: a 13C breath test
A 13C-mannitol breath test now tracks semaglutide gut transit delay in mice, noninvasively. Here is what the method reveals about GLP-1 effects on motility.
Semaglutide safety in dialysis patients
A 2026 Diabetes Care exchange scrutinised pooled trial data on semaglutide safety after dialysis initiation. What the numbers show and what remains open.
Tirzepatide vs semaglutide: the CV gap
Ostrominski et al. found tirzepatide cuts MACE vs dulaglutide but not vs semaglutide. A 2026 comment asked if active-comparator designs conceal real gains.
Can you freeze a reconstituted peptide?
A reader paused a CJC-1295/ipamorelin cycle and wanted to freeze the rest. Here is what the closest approved label and the freeze-thaw literature say.
Selank and Semax: Should You Combine Them?
Selank has real generalized anxiety disorder trial data. Semax's focus reputation does not, and no study has combined the two.
Tirzepatide vs Semaglutide: Liver Risk
A large real-world study found tirzepatide and injectable semaglutide carry the same risk of serious liver outcomes in adults with type 2 diabetes.
Switching to Tirzepatide: Liver Fibrosis
A Japanese study found switching from other GLP-1 drugs to tirzepatide reduced FIB-4 liver fibrosis scores in high-risk patients.
Avexitide: the GLP-1 drug that blocks it
Avexitide, Amylyx's investigational GLP-1 receptor blocker, cut severe post-bariatric hypoglycemia events by 55 percent in a phase 3 trial.
CagriSema meta-analysis: what it found
Seven pooled CagriSema trials show more weight loss than semaglutide or cagrilintide alone. The combination is still unapproved, and pooled data has limits.
ENV-308: a pill built to mimic exercise
Enveda's ENV-308 mimics an exercise-linked metabolite and aims to preserve muscle after GLP-1 weight loss, but its Phase 1 trial tested only safety.
GLP-1 Drugs and Ankle Osteoarthritis Care
A 2026 cohort study ties GLP-1 receptor agonist use to fewer ankle injections and replacements, but more arthroscopy in diabetes.